605507 国邦医药
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入3,142,4293.84%6,011,3975,890,8395,349,4485,720,925
减:营业总成本2,771,3349.96%5,101,1925,007,1214,654,8214,664,769
    其中:营业成本2,395,3508.21%4,446,5334,418,1134,097,1194,144,882
               财务费用45,262-6,458.21%20,649(29,817)(46,282)(68,011)
               资产减值损失(3,970)-30.19%(27,022)(25,825)(31,447)(27,706)
公允价值变动收益8,043-10.05%12,92314,40210,3424,558
投资收益7,06078.15%16,99312,94813,22119,537
    其中:对联营企业和合营企业的投资收益(3,911)-2.95%(6,366)(2,812)60(745)
营业利润390,710-25.17%963,994895,067702,2631,052,878
利润总额387,837-25.60%951,260887,970697,6491,035,639
减:所得税费用46,515-30.90%133,686107,39287,670115,017
净利润341,322-24.82%817,574780,577609,979920,622
减:非控股权益(26)-98.38%(3,247)(1,018)(2,485)(282)
股东净利润341,348-25.07%820,820781,595612,464920,904

市场价值指针
每股收益 (元) *0.440-24.14%1.4801.4001.1001.650
每股派息 (元) *----0.6000.6060.3020.600
每股净资产 (元) *10.736-25.54%15.30614.40113.29912.804
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容